The long-running study on aging and brain health at UK’s Sanders-Brown Center on Aging (SBCoA) Alzheimer’s Disease Center has once again resulted in important new findings – highlighting a complex and under-recognized form of dementia.
When you look back at a 45-year career, there are a multitude of moments that stand out. For Allan Butterfield, Professor of Biological Chemistry in the UK College of Arts & Sciences, his signature discovery grew from just such a Eureka moment on the sidewalk on campus.
An international group of experts led by Dr. Peter Nelson, a neuropathologist at the UK Sanders-Brown Center on Aging, is being recognized as one of the top science stories of 2019 by Discover Magazine.
At UK's men's basketball game versus the University of Louisville on Dec. 28, UK Sanders-Brown Center on Aging Director Linda Van Eldik and researchers Pete Nelson, Donna Wilcock and Steve Scheff were recognized on the Rupp Arena floor.
Lance Cpl. Benjamin Shaw is currently in his fourth year of the UK College of Medicine’s PhD program in physiology, studying the effect genetic differences have on immune cell function related to Alzheimer’s disease risk.
In this episode of "Behind the Blue," Sanders-Brown director Linda Van Eldik talks about the center's involvement in some of the most important discoveries in the history of Alzheimer's research and what they are doing now to advance the science.
In the past, using "Alzheimer’s disease" & "dementia" interchangeably was a generally accepted practice. Now there's rising appreciation that a variety of diseases & disease processes contribute to dementia.
Linda Van Eldik, director of the UK Sanders-Brown Center on Aging, received $5.5 million from NIH and the Alzheimer's Drug Discovery Foundation. She developed a drug that is ready for its first round of testing in humans.
